Computational feat speeds finding of genes to milliseconds instead of years
med.stanford.edu
med.stanford.edu
Only a relatively small amount of the 30,000 human genes are clearly understood. And when you THINK you understand what it does, these genes can sometimes surprise by having other unexpected effects.
What his method seems to do, is to help map out what genes are related to each other. There are cases in cancer for example where we may know that ONE gene gets hyper-activated when a type of cancer is around. If you can correlate the activity of this active gene with other previously unknown gene, you get a better understanding of what causes the disease. If you know what causes the disease, you can use a variety of techniques (drugs, designed proteins, or RNAi) to inhibit the Gene's effects and stop the disease.
Secondly, PNAS is a good journal, but not a great one. He was almost certainly rejected from the top tier. (Nature, Science)
As someone who works in this field, finding genes that are similar in some way to two disease related genes is not at all novel. This is the goal of literally hundreds of computational methods. It sounds like what he did was to build a decision tree from a set of training data - hardly an earth-shattering application.
Edit: Wow, after fully reading the paper I am stunned how commonplace this analysis is. This exact approach has been taken for analyzing microarray data for the last decade. This does not warrant in any way the breathless writeup it receives in the original post.
Under what hypothesis would one expect nature to follow boolean rules? This approach ignores any subtle relationships or multifactorial causes of gene expression changes. The more I read the more I am convinced that this is utter garbage.
What really makes me mad about this is that increasingly the way to get ahead in science is to overstate your results and then have friends of the corresponding author "review" the manuscript. If you'll notice, this was submitted by Irving L Weissman who, according to his website is "Director, Institute of Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine". It is very odd that it wasn't submitted by either the corresponding, nor the lead author. It is very clear that this article did not receive the scientific scrutiny that it should have.
A key question here is how many other pathways did they try this on before they got it to "work" on 10/14 (though really 10/60) B-cell-associated genes? I'm not asserting that they mined for the most favorable pathway, but I will say that this one example comes across as more of an anecdote than a proof of concept.
People are going to be using this tool perhaps hundreds of thousands of times. Don't show me one example where 10/14 genes "validated." Show me 20 examples where X out of N genes validate - if that's sufficiently high, I'll be much more interested.
Even the developmental focus of this new tool is fairly common practice by those in the field. Look at the Seidman lab or the Walsh lab at Boston Children's to see examples of other people thinking deeply about how developmental biology ties back into adult pathology.